Since the combination of PARP inhibitors and radiotherapy may be a promising regimen to locally enhance DNA damage in tumour cells, we further assessed the effect of triple-targeting agents on tumour recurrence after radiotherapy. The gene discussed is PARP1; the disease is neoplasm.